H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics Inc. (NASDAQ:BEAM) on January 15, citing the company’s developments over its BEAM-302 therapy. This comes after Beam announced that it reached an agreement with the FDA on an expedited approval process for BEAM-302 in alpha-1 antitrypsin deficiency (AATD). Pixabay/Public Domain Beam Therapeutics Inc. (NASD ...